Ionis Pharmaceuticals (IONS) Revenue & Revenue Breakdown
Ionis Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$944.00M
Latest Revenue (Q)
$267.95M
Main Segment (Y)
Commercial Member
Ionis Pharmaceuticals Revenue by Period
Ionis Pharmaceuticals Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2025-12-31 | $944.00M | 33.87% |
| 2024-12-31 | $705.14M | -10.48% |
| 2023-12-31 | $787.65M | 34.10% |
| 2022-12-31 | $587.37M | -27.53% |
| 2021-12-31 | $810.46M | 11.13% |
| 2020-12-31 | $729.26M | -35.04% |
| 2019-12-31 | $1.12B | 87.20% |
| 2018-12-31 | $599.67M | 16.63% |
| 2017-12-31 | $514.18M | 37.93% |
| 2016-12-31 | $372.78M | 31.40% |
| 2015-12-31 | $283.70M | 32.47% |
| 2014-12-31 | $214.16M | 45.41% |
| 2013-12-31 | $147.28M | 44.33% |
| 2012-12-31 | $102.05M | 2.99% |
| 2011-12-31 | $99.09M | -8.65% |
| 2010-12-31 | $108.47M | -10.80% |
| 2009-12-31 | $121.60M | 13.44% |
| 2008-12-31 | $107.19M | 83.72% |
| 2007-12-31 | $58.34M | 292.65% |
| 2006-12-31 | $14.86M | -62.98% |
| 2005-12-31 | $40.13M | -5.84% |
| 2004-12-31 | $42.62M | -14.73% |
| 2003-12-31 | $49.99M | -37.65% |
| 2002-12-31 | $80.18M | 50.51% |
| 2001-12-31 | $53.27M | 43.00% |
| 2000-12-31 | $37.26M | 9.90% |
| 1999-12-31 | $33.90M | -13.52% |
| 1998-12-31 | $39.20M | 19.88% |
| 1997-12-31 | $32.70M | 44.05% |
| 1996-12-31 | $22.70M | 74.62% |
| 1995-12-31 | $13.00M | 28.71% |
| 1994-12-31 | $10.10M | -16.53% |
| 1993-12-31 | $12.10M | - |
Ionis Pharmaceuticals generated $944.00M in revenue during NA 2025, up 33.87% compared to the previous quarter, and up 129.45% compared to the same period a year ago.
Ionis Pharmaceuticals Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2026-06-30 | $267.95M | 8.88% |
| 2026-03-31 | $246.09M | 21.23% |
| 2025-12-31 | $203.00M | 29.53% |
| 2025-09-30 | $156.72M | -65.33% |
| 2025-06-30 | $452.05M | 243.47% |
| 2025-03-31 | $131.61M | -41.91% |
| 2024-12-31 | $226.58M | 69.32% |
| 2024-09-30 | $133.81M | -40.59% |
| 2024-06-30 | $225.25M | 88.50% |
| 2024-03-31 | $119.50M | -63.18% |
| 2023-12-31 | $324.50M | 125.03% |
| 2023-09-30 | $144.21M | -23.46% |
| 2023-06-30 | $188.41M | 44.35% |
| 2023-03-31 | $130.52M | -14.07% |
| 2022-12-31 | $151.89M | -4.93% |
| 2022-09-30 | $159.77M | 19.42% |
| 2022-06-30 | $133.79M | -5.73% |
| 2022-03-31 | $141.92M | -67.75% |
| 2021-12-31 | $440.01M | 230.60% |
| 2021-09-30 | $133.09M | 5.84% |
| 2021-06-30 | $125.75M | 12.67% |
| 2021-03-31 | $111.61M | -61.55% |
| 2020-12-31 | $290.28M | 81.34% |
| 2020-09-30 | $160.08M | 9.99% |
| 2020-06-30 | $145.54M | 9.13% |
| 2020-03-31 | $133.37M | -72.99% |
| 2019-12-31 | $493.68M | 194.05% |
| 2019-09-30 | $167.89M | 2.49% |
| 2019-06-30 | $163.81M | -44.88% |
| 2019-03-31 | $297.21M | 54.71% |
| 2018-12-31 | $192.12M | 32.13% |
| 2018-09-30 | $145.40M | 23.48% |
| 2018-06-30 | $117.75M | -18.47% |
| 2018-03-31 | $144.42M | -16.18% |
| 2017-12-31 | $172.30M | 42.50% |
| 2017-09-30 | $120.91M | 16.09% |
| 2017-06-30 | $104.15M | -5.58% |
| 2017-03-31 | $110.30M | -31.21% |
| 2016-12-31 | $160.35M | 44.55% |
| 2016-09-30 | $110.93M | 188.35% |
| 2016-06-30 | $38.47M | 4.33% |
| 2016-03-31 | $36.87M | -28.50% |
| 2015-12-31 | $51.57M | 4.99% |
| 2015-09-30 | $49.12M | -59.21% |
| 2015-06-30 | $120.43M | 92.43% |
| 2015-03-31 | $62.58M | -26.25% |
| 2014-12-31 | $84.86M | 92.59% |
| 2014-09-30 | $44.06M | -22.80% |
| 2014-06-30 | $57.08M | 102.68% |
| 2014-03-31 | $28.16M | -33.35% |
| 2013-12-31 | $42.25M | 79.14% |
| 2013-09-30 | $23.59M | -38.08% |
| 2013-06-30 | $38.09M | -12.15% |
| 2013-03-31 | $43.36M | 118.19% |
| 2012-12-31 | $19.87M | 71.30% |
| 2012-09-30 | $11.60M | -75.49% |
| 2012-06-30 | $47.34M | 103.74% |
| 2012-03-31 | $23.23M | -28.29% |
| 2011-12-31 | $32.40M | 56.44% |
| 2011-09-30 | $20.71M | -16.56% |
| 2011-06-30 | $24.82M | 17.38% |
| 2011-03-31 | $21.15M | -19.96% |
| 2010-12-31 | $26.42M | -7.70% |
| 2010-09-30 | $28.62M | 21.79% |
| 2010-06-30 | $23.50M | -21.46% |
| 2010-03-31 | $29.93M | -7.24% |
| 2009-12-31 | $32.26M | 20.51% |
| 2009-09-30 | $26.77M | -13.62% |
| 2009-06-30 | $30.99M | -1.85% |
| 2009-03-31 | $31.58M | 52.83% |
| 2008-12-31 | $20.66M | -35.87% |
| 2008-09-30 | $32.22M | -2.26% |
| 2008-06-30 | $32.96M | 54.36% |
| 2008-03-31 | $21.35M | -13.64% |
| 2007-12-31 | $24.73M | - |
Ionis Pharmaceuticals generated $267.95M in revenue during Q2 2026, up 8.88% compared to the previous quarter, and up 203.59% compared to the same period a year ago.
Ionis Pharmaceuticals Revenue Breakdown
Ionis Pharmaceuticals Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Product | $115.31M | $34.19M | $34.91M | $30.05M | - |
| Royalty | $285.53M | - | - | - | - |
| Commercial Member | $435.85M | - | - | - | - |
| Collaborative Agreement Revenue | - | $332.65M | $352.66M | $207.22M | - |
| Commercial | - | $293.08M | $308.59M | $303.36M | $342.39M |
| Other Commercial | - | $56.78M | $68.21M | - | - |
| Other | - | $22.59M | - | - | - |
| Research and Development Revenue | - | $412.06M | $479.06M | $284.01M | - |
| SPINRAZA Royalties | - | $216.09M | $240.38M | - | - |
| Licensing and Other Royalties | - | - | $33.30M | $30.99M | $19.12M |
| Spinraza Royalties | - | - | - | $242.31M | $267.78M |
| Eplontersen Joint Development Revenue | - | - | - | $76.79M | - |
| TEGSEDI and WAYLIVRA | - | - | - | - | $55.50M |
| Research and Development Revenue Under Collaborative Agreements | - | - | - | - | $468.06M |
Latest
Ionis Pharmaceuticals's latest annual revenue breakdown by segment (product or service), as of Dec 25: Commercial Member (52.09%), Royalty (34.13%), and Product (13.78%).
Quarterly Revenue by Product
| Product/Service | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 23 | Sep 23 | Jun 23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product | $31.14M | $42.95M | $64.25M | $31.79M | $19.27M | $17.07M | $8.92M | $8.19M | $20.15M | $8.29M | - | - |
| Royalty | $75.96M | $58.32M | $75.72M | $75.69M | $69.95M | $64.17M | - | - | - | - | - | - |
| Commercial Member | $118.62M | $107.81M | $217.49M | $115.60M | $102.76M | - | - | - | - | - | - | - |
| TEGSEDI and WAYLIVRA | - | - | - | - | - | $5.71M | - | - | - | - | - | - |
| Product Sales, Net | - | - | - | - | - | $6.29M | - | - | - | - | - | - |
| Other Commercial | - | - | - | - | - | $5.71M | $32.12M | $13.15M | $11.51M | $34.50M | $16.83M | $16.89M |
| SPINRAZA Royalties | - | - | - | - | - | $48.01M | $102.14M | $57.21M | $56.74M | $112.11M | $67.25M | $61.01M |
| Research and Development Revenue | - | - | - | - | - | $55.44M | $200.76M | $58.08M | $153.21M | $245.66M | $60.13M | $110.51M |
| Collaborative Agreement Revenue | - | - | - | - | - | $45.03M | $146.24M | $44.88M | $141.52M | $179.14M | $44.17M | $91.01M |
| Commercial | - | - | - | - | - | $76.17M | $145.31M | $75.73M | $72.04M | $78.84M | $84.08M | $77.90M |
| Licensing and Other Royalties | - | - | - | - | - | - | - | $4.23M | $3.32M | $13.71M | $8.54M | - |
| Eplontersen Joint Development Revenue | - | - | - | - | - | - | - | - | - | - | $15.96M | $19.50M |
Latest
Ionis Pharmaceuticals's latest quarterly revenue breakdown by segment (product or service), as of Jun 26: Commercial Member (52.55%), Royalty (33.65%), and Product (13.80%).
Ionis Pharmaceuticals Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| BMRN | BioMarin Pharmaceutical | $3.22B | $989.71M |
| EXEL | Exelixis | $2.32B | $628.69M |
| MRNA | Moderna | $1.94B | $145.00M |
| GH | Guardant Health | $982.02M | $334.98M |
| MDGL | Madrigal Pharmaceuticals | $958.40M | $364.25M |
| IONS | Ionis Pharmaceuticals | $944.00M | $267.95M |
| BBIO | BridgeBio Pharma | $362.37M | $222.44M |
| ASND | Ascendis Pharma | $266.72M | $95.89M |
| ROIV | Roivant Sciences | $8.26M | $1.44M |
| RVMD | Revolution Medicines | - | - |
| SMMT | Summit Therapeutics | - | - |